CYP2D6 and tamoxifen: DNA matters in breast cancer

@article{Hoskins2009CYP2D6AT,
  title={CYP2D6 and tamoxifen: DNA matters in breast cancer},
  author={J. Hoskins and L. Carey and H. McLeod},
  journal={Nature Reviews Cancer},
  year={2009},
  volume={9},
  pages={576-586}
}
  • J. Hoskins, L. Carey, H. McLeod
  • Published 2009
  • Biology, Medicine
  • Nature Reviews Cancer
  • Tamoxifen is the most widely used anti-oestrogen for the treatment of hormone-dependent breast cancer. The pharmacological activity of tamoxifen is dependent on its conversion by the hepatic drug-metabolizing enzyme cytochrome P450 2D6 (CYP2D6) to its abundant metabolite, endoxifen. Patients with reduced CYP2D6 activity, as a result of either their genotype or induction by the co-administration of drugs that inhibit CYP2D6 function, produce little endoxifen and seem to derive inferior… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    Explore Further: Topics Discussed in This Paper

    The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
    • 16
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 95 REFERENCES